• Loading stock data…

COVID-19

Time For T cells: Gritstone Bio (GRTS)

Situation Snapshot A new COVID-19 variant (Omicron) was recently identified in South Africa. On 11/26/21 the World Health Organization classified Omicron as a variant of concern (VOC). The decision … [Read more...] about Time For T cells: Gritstone Bio (GRTS)

Gritstone Bio Reports Promising Preclinical Data in NHPs; Efficacy Threshold Exceeded at Low Doses

On 11/11/21 one of our core positions Gritstone Bio (GRTS) reported highly anticipated data from its CORAL COVID-19 vaccine program in non-human primates (NHPs). After scrupulous review and comparison … [Read more...] about Gritstone Bio Reports Promising Preclinical Data in NHPs; Efficacy Threshold Exceeded at Low Doses

La Jolla Pharmaceuticals (Nasdaq: LJPC): An Assessment of The Tetraphase Acquisition

For the past 8-months now our team has been long La Jolla Pharmaceuticals (Nasdaq: LJPC) calling for a substantial upside in the stock price. At times our thesis has played out such as with the … [Read more...] about La Jolla Pharmaceuticals (Nasdaq: LJPC): An Assessment of The Tetraphase Acquisition

DelMar Pharmaceutical (NASDAQ: DMPI) Remains On Track Despite COVID-19 Crisis

Recap: Since November of 2019 MS Money Moves has been following DelMar Pharmaceuticals (Nasdaq: DMPI) closely through a number of key value inflection points. In my initial article I … [Read more...] about DelMar Pharmaceutical (NASDAQ: DMPI) Remains On Track Despite COVID-19 Crisis

BioCryst Pharmaceuticals (Nasdaq: BCRX) Galidesivir for the Treatment of COVID-19

In a matter of months, a novel strain of coronavirus infamously known as COVID-19 has spiraled from a local outbreak in China into a global pandemic. To date, there have been 1.5M+ confirmed cases and … [Read more...] about BioCryst Pharmaceuticals (Nasdaq: BCRX) Galidesivir for the Treatment of COVID-19